Effect of local preparations containing glucocorticoids on local immunity parameters and activity of human papillomavirus


Cite item

Abstract

The aim of the study was to investigate the effects of topical application of preparations containing glucocorticoids on the replicative activity of human papillomavirus oncogenic type. Prospective study included 160 patients of reproductive age. The examination included microbiological testing, qualitative and quantitative screening for human papilloma virus high-risk group (HPV-PCR and Digene-test), immunological study of cervical secret (immunoglobulins class A, M, G and secretory IgA). Was shown that the vaginal microbiocenosis in patients with nonspecific vaginitis presents a wide range of opportunistic microorganisms, such as Staphylococcus, Streptococcus, Peptostreptococcus, Bacteroides, Bacillus, Actinomyces, Corynebacterium, Prevotella. A number of typical representatives of the indigenous microflora is significantly reduced, or absent. The prevalence of concomitant viral infection was approximately 29%, the most frequently detected viruses 16, 31 and 18. The use of local therapy drug containing a glucocorticoid qualitative and quantitative changes in HPV have been no identified. Evaluation of indicators of local immunity showed an imbalance in the production of immunoglobulins with a predominance of IgA, secretory IgA and IgG in patients on the background of nonspecific vaginitis.

About the authors

E I Borovkova

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: katyanikitina@mail.ru
д-р мед. наук, проф. каф. акушерства и гинекологии лечебного фак-та ФГБОУ ВО «РНИМУ им. Н.И.Пирогова» 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

A S Fedotova

Clinic “Chayka”

врач акушер-гинеколог клиники «Чайка» 123317, Russian Federation, Moscow, Presnenskaia nab., d. 8, str. 1

References

  1. Kolenbrander P, Andersen R, Blehert D. Communication among oral bacteria. Microb Molecular Biology Rev 2002; 66 (3): 486-505.
  2. Winer R.L, Feng Q, Hughes J.P et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008; 197: 279.
  3. Widdice L.E, Brown D.R, Bernstein D.I et al. Prevalence of human papillomavirus infection in young women receiving the first quadrivalent vaccine dose. Arch Pediatr Adolesc Med 2012; 166: 774.
  4. Markowitz L.E, Sternberg M, Dunne E.F et al. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009; 200: 1059.
  5. Liu G, Markowitz L.E, Hariri S et al. Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006. J Infect Dis 2016; 213: 191.
  6. Sycuro L.K, Xi L.F, Hughes J.P et al. Persistence of genital human papillomavirus infection in a long - term follow - up study of female university students. J Infect Dis 2008; 198: 971.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).